Continued FDA approval of iptacopan was contingent on 2-year trial data ...

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

Akebia Therapeutics (NASDAQ:AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial ...

Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...

Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...